NurrOn’s ATH-399A is being developed to treat Parkinson’s disease and other neurodegenerative disorders. Credit: Kateryna Kon via Shutterstock.com.

HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders.

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

They will help to progress ATH-399A towards a Phase I trial.

By activating Nurr1, ATH-399A slows disease progression in PD patients.

Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

HanAll Biopharma CEO Sean Jeong stated: “We are excited to move into the next phase of collaboration with NurrOn, continuing to build on the partnership which was originally established in 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This partnership would allow us to join our resources and expertise in developing new medicines for patients with PD worldwide.”

The companies will also help explore the potential of ATH-399A to treat other neurodegenerative diseases.

NurrOn Pharmaceuticals CEO Deog Joong Kim stated: “NurrOn has completed the preclinical development of ATH-399A and plans to enter a Phase I clinical trial this year.

“We expect great synergy through the joint collaboration between NurrOn, HanAll Biopharma and Daewoong Pharmaceuticals, especially given their great clinical development expertise.”

The company has recently received funding from the Michael J Fox Foundation to support the Phase I clinical trial of ATH-399A.